RR: I'm with you, though I will be holding longer. Why stop at $2 when you think it may go to $20 or higher. I doubt this will get to triple figures within 2-3 years, but it could go high, assuming the pharma indications pan out, which is never guaranteed. If they do, then I believe they'll become an acquisition target. In any event, I'm with you that this is a keeper. It is still vulnerable to a lot of manipulation, but the story and supporting facts are strong. Cheers. MT.
News 
Market Data 
Discover 
